Association of whole grain food consumption with lung cancer risk: a prospective cohort study by Kanran Wang, Junhan Zhao, Dingyi Yang, Mao Sun, Yongzhong Wu, Wei Zhou

“…Therefore we aim to investigate the relationship between whole grain food consumption and lung cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort. Methods Diet was assessed with a self-administered Diet History Questionnaire (DHQ) at baseline. …”
Get full text

Feature Selection in Cancer Classification: Utilizing Explainable Artificial Intelligence to Uncover Influential Genes in Machine Learning Models by Matheus Dalmolin, Karolayne S. Azevedo, Luísa C. de Souza, Caroline B. de Farias, Martina Lichtenfels, Marcelo A. C. Fernandes

“…This study investigates the use of machine learning (ML) models combined with explainable artificial intelligence (XAI) techniques to identify the most influential genes in the classification of five recurrent cancer types in women: breast cancer (BRCA), lung adenocarcinoma (LUAD), thyroid cancer (THCA), ovarian cancer (OV), and colon adenocarcinoma (COAD). …”
Get full text

Synthesis of bioactive quinazolin-4(3H)-one derivatives via microwave activation tailored by phase-transfer catalysis by El-Badry Yaser A., El-Hashash Mahr A., Al-Ali Khalil

“…The screened compounds exhibited a significant antitumor activity on some of the cancer cell lines, melanoma (SK-MEL-2), ovarian cancer (IGROV1), renal cancer (TK-10), prostate cancer (PC-3), breast cancer (MCF7) and colon cancer (HT29). …”
Get full text

Extracellular vesicles display distinct glycosignatures in high-grade serous ovarian carcinoma by Kristina Mae Bienes, Akira Yokoi, Masami Kitagawa, Hiroaki Kajiyama, Morten-Thaysen Andersen, Rebeca Kawahara

“…High-grade serous ovarian carcinoma (HGSOC) is a deadly subtype of ovarian cancer (OC), often diagnosed at late stages due to nonspecific symptoms and lack of effective markers for early detection. …”
Get full text

G Protein-Coupled Estrogen Receptor-Selective Ligands Modulate Endometrial Tumor Growth by Whitney K. Petrie, Megan K. Dennis, Chelin Hu, Donghai Dai, Jeffrey B. Arterburn, Harriet O. Smith, Helen J. Hathaway, Eric R. Prossnitz

“…High GPER expression is predictive of poor survival in endometrial and ovarian cancer, but despite this, the estrogen-mediated signaling pathways and specific estrogen receptors involved in endometrial cancer remain unclear. …”
Get full text

An experimental study of the effects of SNPs in the TATA boxes of the <i>GRIN1, ASCL3</i> and <i>NOS1</i> genes on interactions with the TATA-binding protein by E. B. Sharypova, I. A. Drachkova, I. V. Chadaeva, M. P. Ponomarenko, L. K. Savinkova

“…For example, ASCL3 is overexpressed in breast cancer, and NOS1, in ovarian cancer cell lines. Based on our findings and literature data, we had previously obtained results suggesting that the single-nucleotide polymorphisms (SNPs) that disrupt erythropoiesis are highly likely to be associated with cognitive and neuropsychiatric disorders in humans. …”
Get full text

655Val and 1170Pro ERBB2 SNPs in Familial Breast Cancer Risk and BRCA1 Alterations by Stefania Tommasi, Vita Fedele, Rosanna Lacalamita, Michele Bruno, Francesco Schittulli, David Ginzinger, Gery Scott, Serenella Eppenberger-Castori, Daniele Calistri, Silvia Casadei, Ian Seymour, Salvatore Longo, Gianluigi Giannelli, Brunella Pilato, Giovanni Simone, Christopher C. Benz, Angelo Paradiso

“…The aim of this study was to investigate the association of rare alleles of both SNPs and the risk of developing breast cancer, BRCA1 alterations and clinical-pathological features of Caucasian breast cancer patients with familial history of breast/ovarian cancer. The originality of the present paper is that it is the only specifically focusing on the relationship between ERBB2 SNPs and familiarity/BRCA1 characteristics. …”
Get full text

Primary epidemiological evaluation of the effectiveness of the All-National Dispensarization as a cancer screening by the data of the Arkhangelsk Regional Cancer Registry by L. E. Valkova, M. L. Levit, V. M. Merabishvili, A. Yu. Pankrateva, D. M. Dubovichenko, A. V. Agaeva, A. Yu. Ryzhov, E. F. Potekhina, M. Yu. Valkov

“…The effectiveness of early diagnosis is not confirmed for the lung, uterus, ovarian cancers. For screening-sensitive MNs, an analysis of mortality and survival is necessary.…”
Get full text

Etiology of Ascites and Pleural Effusion Associated with Ovarian Tumors: Literature Review and Case Reports of Three Ovarian Tumors Presenting with Massive Ascites, but without Per... by Ai Miyoshi, Takashi Miyatake, Takeya Hara, Asuka Tanaka, Naoko Komura, Shinnosuke Komiya, Serika Kanao, Masumi Takeda, Mayuko Mimura, Masaaki Nagamatsu, Takeshi Yokoi

“…Borderline ovarian tumors are benign but relatively large tumors that are often initially mistaken as ovarian cancers. We report three cases of stage I borderline ovarian tumors having massive ascites that we (preoperatively) suspected of being advanced ovarian cancer. …”
Get full text

Evaluating the association between lipidome and female reproductive diseases through comprehensive Mendelian randomization analyses by Ye Ma, Fang Wu, Zeming Yu, Lu Yang

“…This study utilized genome-wide association study (GWAS) summary statistics encompassing 179 lipidomes and six prevalent FRDs, namely polycystic ovary syndrome (PCOS), endometriosis, uterine fibroid, female infertility, uterine endometrial cancer, and ovarian cancer. The two-sample MR (TSMR) approach was employed to investigate the causal relationships, with further validation using false discovery rate (FDR) and multivariable MR (MVMR) methods. …”
Get full text

Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome– paving the path towards precision medicine: a case report by Carolin Seeling, Sonja Dahlum, Ralf Marienfeld, Vera Jan, Brigitte Rack, Uwe Gerstenmaier, Ambros J. Beer, Regine Mayer-Steinacker, Wolfgang Thaiss, Thomas F. E. Barth, Thomas Seufferlein, Nadine T. Gaisa, Stephan Stilgenbauer, Wolfgang Janni, Reiner Siebert, Hartmut Döhner, Verena I. Gaidzik

“…Palbociclib therapy was discontinued after one year with no evidence of disease. One year later, ovarian cancer was diagnosed, with molecular analysis indicating interstitial heterozygous loss of the BRCA2 gene locus, providing a rationale for targeted therapy with the PARP inhibitor olaparib. …”
Get full text

Ion suppression correction and normalization for non-targeted metabolomics by Iqbal Mahmud, Bo Wei, Lucas Veillon, Lin Tan, Sara Martinez, Bao Tran, Alexander Raskind, Felice de Jong, Yiwei Liu, Jibin Ding, Yun Xiong, Wai-kin Chan, Rehan Akbani, John N. Weinstein, Chris Beecher, Philip L. Lorenzi

“…To demonstrate a routine application of the Workflow, we employ the Workflow to study ovarian cancer cell response to the enzyme-drug L-asparaginase (ASNase). …”
Get full text

Automatic segmentation model and machine learning model grounded in ultrasound radiomics for distinguishing between low malignant risk and intermediate-high malignant risk of adnex... by Lu Liu, Wenjun Cai, Feibo Zheng, Hongyan Tian, Yanping Li, Ting Wang, Xiaonan Chen, Wenjing Zhu

“…Critical relevance statement The ultrasound radiomics-based machine learning model holds the potential to elevate the professional ability of less-experienced radiologists and can be used to assist in the clinical screening of ovarian cancer. Key Points We developed an image segmentation model to automatically delineate adnexal masses. …”
Get full text

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer by Anne Mills, Leisha A Emens, Mary L Disis, Kunle Odunsi, John B Liao, Tyler Curiel, Margaret Gatti-Mays, Amir Jazaeri, Emese Zsiros, Marcus O Butler, Jyoti Bajpai, Katherine C Kurnit, Haider Mahdi, Laura Doherty, Claire F Friedman, Melissa A Geller, Sarah F Adams, Shelley A Dodt, Veena S John

“…In addition, many immunotherapy strategies are under investigation for the treatment of earlier stages of disease or in other gynecologic cancers, such as ovarian cancer and rare gynecologic tumors. While the integration of ICIs into the standard of care has improved outcomes for patients, their use requires a nuanced understanding of biomarker testing, treatment selection, patient selection, response evaluation and surveillance, and patient quality of life considerations, among other topics. …”
Get full text

Tousled-like kinase loss confers PARP inhibitor resistance in BRCA1-mutated cancers by impeding non-homologous end joining repair by Min-ah Kim, Banseok Kim, Jihyeon Jeon, Jonghyun Lee, Hyeji Jang, Minjae Baek, Sang-Uk Seo, Dongkwan Shin, Anindya Dutta, Kyung Yong Lee

“…Consequently, TLK deficiency induces PARPi resistance in triple-negative breast cancer (TNBC) and ovarian cancer (OVCA) cell lines with BRCA1 deficiency, as TLK deficiency in BRCA1-depleted cells, impairs 53BP1 recruitment to DSBs and reduces NHEJ efficiency, while restoring HR. …”
Get full text

Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes by Fresia Pareja, Rohit Bhargava, Virginia F. Borges, Edi Brogi, Rita Canas Marques, Fatima Cardoso, Christine Desmedt, Malini Harigopal, Sunil R. Lakhani, Adrian Lee, Jose Pablo Leone, Hannah Linden, Christopher J. Lord, Caterina Marchio, Sofia D. Merajver, Emad Rakha, Jorge S. Reis-Filho, Andrea Richardson, Elinor Sawyer, Pepper Schedin, Christopher J. Schwartz, Andrew Tutt, Naoto T. Ueno, Anne Vincent-Salomon, Britta Weigelt, Y. Hannah Wen, Stuart J. Schnitt, Steffi Oesterreich

Get full text

The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial by Elena Giudice, Tzu-Ting Huang, Jayakumar R. Nair, Grant Zurcher, Ann McCoy, Darryl Nousome, Marc R. Radke, Elizabeth M. Swisher, Stanley Lipkowitz, Kristen Ibanez, Duncan Donohue, Tyler Malys, Min-Jung Lee, Bernadette Redd, Elliot Levy, Shraddha Rastogi, Nahoko Sato, Jane B. Trepel, Jung-Min Lee

“…Abstract The multi-cohort phase 2 trial NCT02203513 was designed to evaluate the clinical activity of the CHK1 inhibitor (CHK1i) prexasertib in patients with breast or ovarian cancer. Here we report the activity of CHK1i in platinum-resistant high-grade serous ovarian carcinoma (HGSOC) with measurable and biopsiable disease (cohort 5), or without biopsiable disease (cohort 6). …”
Get full text

Integrating BRCA testing into routine prostate cancer care: a multidisciplinary approach by SIUrO and other Italian Scientific Societies by Giulia Mammone, Simona Borghesi, Nicolò Borsellino, Anna Caliò, Roberta Ceccarelli, Alessia Cimadamore, Giario Natale Conti, Laura Cortesi, Rolando Maria D’Angelillo, Gaetano Facchini, Lorena Incorvaia, Alberto Lapini, Luigi Mearini, Giovanni Pappagallo, Paolo Prontera, Daniela Turchetti, Grazia Sirgiovanni, Sergio Bracarda, on behalf of the Italian Society of Uro-Oncology (SIUrO)

“…Abstract Prostate cancer (PCa) ranks among the most prevalent malignancies in men, with notable associations to Hereditary Breast and Ovarian Cancer Syndrome (HBOC) and Lynch Syndrome, both linked to germline likely pathogenetic variant/pathogenetic variant (LPV/PV) in genes involved in DNA repair. …”
Get full text

Super-enhancers and efficacy of triptolide in small cell carcinoma of the ovary hypercalcemic type by Jessica D. Lang, William Selleck, Shawn Striker, Nicolle A. Hipschman, Rochelle Kofman, Anthony N. Karnezis, Felix K.F. Kommoss, Friedrich Kommoss, Jae Rim Wendt, Salvatore J. Facista, William P.D. Hendricks, Krystal A. Orlando, Patrick Pirrotte, Elizabeth A. Raupach, Victoria L. Zismann, Yemin Wang, David G. Huntsman, Bernard E. Weissman, Jeffrey M. Trent

“…Summary: Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT) is a rare ovarian cancer affecting young females and is driven by the loss of both SWI/SNF ATPases SMARCA4 and SMARCA2. …”
Get full text

High Spatiotemporal Near‐Infrared II Fluorescence Lifetime Imaging for Quantitative Detection of Clinical Tumor Margins by Zhen Chen, Linjian Huang, Duyang Gao, Zhouzhou Bao, Dehong Hu, Wei Zheng, Jing Chen, Jiuling Liao, Hairong Zheng, Zonghai Sheng

“…In vitro and in vivo studies confirm that FPH‐ICG specifically targets folate receptor‐α (FRα) on SK‐OV‐3 ovarian cancer cells, achieving high‐contrast NIR‐II FL imaging with a signal‐to‐background ratio of 10.8. …”
Get full text